News

Under the terms of the agreement, Isis will receive a technology access fee of $1 million, research funding, and milestone payments. In addition, Isis will receive royalties on

This is the second placebo-controlled study to produce findings suggesting that atomoxetine is effective in providing continuous symptom relief in children with attention deficit hyperactivity disorder (ADHD). The

In a pooled analysis of placebo-controlled studies, patients taking Equetro, a carbamazepine extended-release capsule, who had been previously taking valproate or lithium (both with or without improvement of

The data shows that patients treated with olanzapine and fluoxetine capsules (OFC) not have fewer symptoms but also respond faster to the therapy than patients treated with lamotrigine.

The study, named COBRA, was designed to compare the efficacy and safety of telithromycin (Ketek) to other standard, single agent antibiotics, such as B-lactams, cephalosporins, macrolides, and quinolones,

Macugen will be first therapy in Brazil indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) regardless of lesion subtype or size. The drug, which was

VistaGen claims AV-101 (4-Cl-KYN) represents a potential first-in-class therapy for the multi-billion dollar neuronal disorder markets, including major disorders such as epilepsy and neuropathic pain. The preclinical data

This is the first of two phase I/II trials to be initiated using the NF-kappaB Decoy (NF-kB Decoy). A second trial will be conducted in Australia and Switzerland

The data suggests recombinant nematode anticoagulant protein c2 or rNAPc2, has an acceptable safety profile and is well tolerated in doses up to 10 microgram/kg, in patients with